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epothilone D alters normal 
growth, viability and microtubule 
dependent intracellular functions of 
cortical neurons in vitro
J. A. clark, J. A. chuckowree  , M. S. Dyer, t. c. Dickson & c. A. Blizzard*
Brain penetrant microtubule stabilising agents (MSAs) are being increasingly validated as potential 
therapeutic strategies for neurodegenerative diseases and traumatic injuries of the nervous system. 
MSAs are historically used to treat malignancies to great effect. However, this treatment strategy can 
also cause adverse off-target impacts, such as the generation of debilitating neuropathy and axonal 
loss. Understanding of the effects that individual MSAs have on neurons of the central nervous system 
is still incomplete. previous research has revealed that aberrant microtubule stabilisation can perturb 
many neuronal functions, such as neuronal polarity, neurite outgrowth, microtubule dependant 
transport and overall neuronal viability. in the current study, we evaluate the dose dependant impact 
of epothilone D, a brain penetrant MSA, on both immature and relatively mature mouse cortical 
neurons in vitro. We show that epothilone D reduces the viability, growth and complexity of immature 
cortical neurons in a dose dependant manner. furthermore, in relatively mature cortical neurons, we 
demonstrate that while cellularly lethal doses of epothilone D cause cellular demise, low sub lethal 
doses can also affect mitochondrial transport over time. Our results reveal an underappreciated 
mitochondrial disruption over a wide range of epothilone D doses and reiterate the importance of 
understanding the dosage, timing and intended outcome of MSAs, with particular emphasis on brain 
penetrant MSAs being considered to target neurons in disease and trauma.
Historically, the adult neuronal cytoskeleton was considered relatively stable, being involved only in neuropro-
genitor cell division during de novo neurogenesis1,2. With our increased understanding of the neuronal microtu-
bule environment and function, and the adult brains capacity for neuroplasticity3, it is now evident that neuronal 
microtubules, the largest of the three filament components of the cytoskeleton, form a critical dynamic intra-
cellular network4. In this regard, microtubules consist of both stable and labile domains5,6 within tubular proto-
filaments comprised of α- and β-tubulin heterodimers. Microtubules display a phenomenon termed “dynamic 
instability”7, which describes the stochastic variations between bouts of growth, pausing and shrinkage of the 
microtubule population. Microtubules can transition from a growing to a shrinking state, termed catastrophe, 
which may or may not be rescued back to a growing state. The microtubule protofilament consists of a slow grow-
ing “minus end” and a fast growing, highly dynamic “plus end”8,9, which plays a critical role in normal neuronal 
functions including neuronal growth, intracellular transport, establishment and maintenance of cellular polarity, 
and process remodelling10–12. Changes to the growth state of microtubules can have downstream consequences 
for their normal physiological functions, such as the binding of specific motor transport units13, and the associ-
ation of + TIP proteins that facilitate interactions between microtubules and other intracellular structures, and 
regulate important neuronal outcomes such as axonal branching14,15.
Manipulation of microtubule dynamics and structural integrity can be accomplished by using compounds 
termed ‘microtubule stabilising agents’ (MSAs). At high doses, MSAs are among the most successful means by 
which to target and treat various types of malignancies16. This is mainly due to the importance of microtubules 
in the development and mechanical action of the mitotic spindle during cell division, which progresses into an 
uncontrolled and hyper activated process in cancer17. Unfortunately, this treatment strategy has ramifications 
for otherwise healthy cells of the body. In neurons, abolishing microtubule dynamics causes painful peripheral 
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neuropathies; an adverse effect associated with chemotherapy treatment in cancer patients (reviewed previously 
in18,19). This is particularly prevalent in sensory neurons, where MSAs cause microtubule protein alterations, 
microtubule disintegration and axonal degeneration20. In this regard, MSAs have been shown to induce aberrant 
shifts in the polarity of axonal microtubules from a “plus end out” uni-directional orientation, to a mixed orien-
tation similar to that of dendrite microtubules. Ultimately this altered orientation impacts on microtubule based 
transport21. MSAs have also been documented to influence the cortical circuitry of the central nervous system 
(CNS). For example, low doses of the MSA taxol have been shown to alter the dynamics of dendritic spines22, and 
can augment memory formation23.
This identification of positive effects of MSAs on the nervous system has led to an explosion of research involv-
ing the use of brain penetrant MSAs to treat various neurodegenerative disorders of the CNS24. A family of MSAs 
currently utilised in many studies are the epothilones, a group of compounds found naturally in the myxobacte-
rium Sorangium cellulosum25. Previous investigations report a dose dependant response to epothilone D (EpoD) 
treatment after a scratch injury in cortical neurons in vitro, with low micromolar to subnanomolar concentrations 
of EpoD increasing axonal sprouting post-injury26. Others have reported positive results when utilising EpoD 
to improve outcomes in in vivo models of Parkinson’s Disease27, tauopathy and Alzheimer’s Disease28,29, and 
schizophrenia30,31. However, a recent study reports that low doses of the epothilone analogue epothilone B cause 
alterations to neuronal viability and growth32. Collectively, these studies indicate that epothilones may have an 
unappreciated dose dependant range of outcomes.
Concerns regarding the therapeutic use of MSAs centres around the lack of understanding of individual brain 
penetrant MSAs and their dose dependent effect on neuronal health in the CNS33. Indeed, investigations into the 
impact EpoD has on neuronal viability, growth and function are yet to be completed in cortical neurons, a neu-
ronal population increasingly targeted by MSAs. In the current study we aimed to directly address this shortfall 
by identifying the toxic dose range of EpoD in vitro using cortical neuron cultures. We proposed that EpoD would 
provoke dose dependant alterations to outcome measures, such as cortical neuron survival, growth and com-
plexity, alterations to microtubule associated protein expression and microtubule dependant organelle transport. 
Using a mouse primary cortical neuron culture system, we report novel findings of neuronal dysfunction due to 
EpoD treatment in vitro, with implications for future studies utilising low-dose antimitotic compounds, such as 
EpoD, for the treatment of neurodegenerative disorders.
Methods
Animals. Animal use was approved by the Animal Ethics Committee of the University of Tasmania and was 
performed in accordance with the ‘Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes (2013)’. All animal experiments utilised transgenic yellow fluorescent protein (YFP) mice (thy1-YFP-
16Jra/J; stock number 003709) (The Jackson Laboratory), which express YFP in large projection neurons (namely 
pyramidal cells) in the CNS34. All mice were maintained on a C57Bl/6 background.
primary cortical neuron cultures. Embryonic cortical neurons were isolated from the dissected and disso-
ciated neocortex of 15.5-day-old embryonic YFP mice and plated onto a poly-l-lysine coated surface (glass cover-
slips etched in 70% nitric acid or plastic) in 24 well plates (1.9 cm2), 6 well plates (3.48 cm2) or live imaging micro 
chambers (1.5 cm2). Neurons were maintained in neurobasal medium (Thermo Fischer Scientific), containing 
2% B27 supplement (Thermo Fischer Scientific), L-glutamine (Sigma) and 1x penicillin-streptomycin (Thermo 
Fischer Scientific), and incubated at 37 °C in 5% CO2 for the duration of experiments.
treatment paradigms. In order to study the effects of EpoD (ABCAM, stock number ab143616, >99% 
purity) on normal neuronal development, neurite growth and function, cells were exposed to a variety of drug 
concentrations (0.1 nM, 1 nM, 10 nM, 100 nM EpoD), for two hours and 24 hours in relatively mature neurons 
(10DIV), or 24 hours with media replacement (conditioned media plus treatment) for growth and development 
experiments from one to four DIV. Naïve, untreated neurons and vehicle (0.1% v/v DMSO in culture media) 
treated neurons were utilised as controls. All experiments used a minimum of three separate cultures, with exper-
iments completed in triplicate, unless otherwise stated.
Quantification of cell viability. Cell health was determined by using the AlamarBlue® cell viability assay 
(Thermo Fisher Scientific) according to the manufacturer’s instructions and measured by fluorescence on a 
FLUOstar OPTIMA plate reader (excitation 570 nm, emission 580; BMG Labtech). Data are reported as percent-
age of cell viability corrected to vehicle treated controls. The AlamarBlue® cell viability assay was complemented 
with the evaluation of nuclear morphology using DAPI staining, to determine cell viability, as described previ-
ously35. Briefly, nuclei were graded as “healthy” when DAPI labelling could determine the nuclear boundary, with 
diffuse staining throughout the nucleus (see Fig. 1E); or graded as “unhealthy/dying” if nuclei appeared pyknotic/
fragmented, with no definable nuclear boundary (see Fig. 1E, arrows).
immunocytochemistry and confocal microscopy. Neuronal cultures were fixed in 4% PFA, fol-
lowed by permeabalisation for 10 minutes (0.3% or 1% Triton-x-100 in 0.01 M PBS containing 5% BSA) and 
then incubated in primary antibody in 0.01 M PBS containing 5% BSA overnight at 4 °C. Antibodies were used 
to identify cell processes (rat-monoclonal GFP, 1:3000, Nacalai Tesque), axons (rabbit-polyclonal tau, 1:2000, 
DAKO). Neurofilaments were labelled with antibody to neurofilament medium chain (NFM) (rabbit-polyclonal 
NFM, 1:1000, Millipore). Secondary antibodies (anti-rat Alexa488, anti-rat Alexa594, anti-mouse Alexa568, 
anti-rabbit Alexa647) were diluted in PBS (1:750; Molecular Probes) and cultures were incubated for 1.5 hours at 
room temperature, followed by DAPI nuclear staining, washing with PBS, and mounting with mounting media 
(Permafluor, DAKO). Cells were visualised using a spinning disk laser confocal (UltraVIEW® VOX, Perkin 
Elmer) on an inverted microscope (Nikon TiE, Nikon) fitted with 20 × (Plan-Apo N.A. 0.75) and 40 × (Plan-Apo 
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N.A. 0.95) objective lenses. Images were acquired using an Orca R2 camera (C10600, Orca, Hamamatsu) and 
processed using image capture software (Velocity v6.3.0, 2013, Perkin Elmer).
image analysis and cell tracing. Neurite extension was evaluated in YFP expressing cells with healthy 
nuclear morphology and robust YFP cytoplasmic fluorescence in Image J (NIH)36. Tracings of neuronal cell bod-
ies, developing axons (tau positive YFP processes) and dendrites (tau negative YFP processes) were completed 
utilising Neurolucida software (MBF Bioscience). The area of Neurofilament-M (NFM) and YFP immunostaining 
was evaluated by firstly thresholding images using settings determined from vehicle treated cultures, followed by 
Figure 1. Neuronal viability and neurite process extension of EpoD treated immature cortical neurons. 
(A) There is no decrease in cell viability at 1DIV. (B) At 2DIV 100 nM EpoD treated cortical neurons have a 
significant (p < 0.05) decrease in cell viability. (C) 10 nM and 100 nM EpoD treated cortical neurons exhibit 
a significant (p < 0.05) reduction in cell viability at 3DIV, and (D) further reduction (p < 0.05) in viability 
of 10 nM and 100 nM treated cultures at 4 DIV. (E) The proportion of YFP positive cells with healthy nuclei 
is significantly reduced (p < 0.001) in 100 nM EpoD treated cultures at 1DIV. (F) The proportion of healthy 
YFP positive neurons with neurites are significantly (p < 0.05) reduced in 100 nM EpoD treated cortical 
neuronal cultures at 1DIV, but is comparable to vehicle treated control cultures by 2, 3 and 4DIV. (G) 
Immunocytochemistry example of a healthy YFP positive cortical neuron with no process extension (top 
images) and a YFP positive cortical neuron with an extending tau positive process (bottom images, solid 
arrowhead) and shorter, more numerous tau negative processes (open arrowheads). Using the 3–4 DIV cell 
viability assays, EpoD concentrations were classified as either sublethal (did not cause loss of cell viability) 
or lethal (caused significant loss in cell viability. Scale = 90 μm. (Data reported as mean ± SD, ANOVA with 
Dunnett post hoc test, *p < 0.05, ***p < 0.001. All data n = 3 cultures, performed in triplicate. Abbreviations: 
DIV, days in vitro; EpoD, epothilone D; SEM, standard error of the mean; nM, nanomolar; YFP, yellow 
fluorescent protein. *p < 0.05, **p < 0.01, ***p < 0.001.
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particle analysis to calculate staining area in ImageJ. To determine the level of NFM in YFP neurons specifically, a 
Coloc 2 plugin was used to determine the Pearson’s correlation coefficient between NFM and YFP. The immunos-
taining area change and correlation coefficient is represented as a ratio to vehicle treated controls.
Mitochondrial transport analysis. Culture media containing EpoD/vehicle treatment was removed from 
the cells and kept at 37 °C for reapplication following mitochondrial staining. Cells were incubated in condi-
tioned culture media containing Mitotracker® Red FM (200 nM final concentration, Thermo Fischer Scientific) 
for 15 minutes, followed by a 5 minute wash in conditioned culture media. EpoD/vehicle media was reapplied to 
the cells and live cell imaging was performed utilising fluorescence, differential interference contrast (DIC) and 
phase-contrast microscopy on a Nikon Eclipse Ti inverted microscope (Nikon) within an enclosed incubator 
maintained at 37 °C and 5% CO2. Live cell images were captured using a Zyla CMDS camera (Andor), and con-
trolled by NIS elements (Nikon) (two minutes, one second intervals). Images were subsequently analysed using 
FIJI software (NIH), with the plugin MTrackJ37. Moving mitochondria were traced until they no longer moved for 
three or more frames, or until the end of the imaging session. Data from mitochondria with multiple movement 
phases was averaged.
Western blot protein quantification. Neuronal cultures were rinsed in ice-cold PBS, followed by 
lysis in RIPA-Inhibition buffer (RIPA buffer + 1 μM trichostatin-a (Sigma Aldrich) + protease inhibitor 
cocktail (Sigma Aldrich)), and centrifugation at 15,000 g for 10 minutes at 4 °C to remove cell debris, as 
described previously28. Proteins were separated by SDS-PAGE using a Novex NuPAGE gel system (Thermo 
Fisher Scientific), followed by probing by Western blot. Protein levels were then evaluated using antibodies 
to acetylated tubulin (mouse-monoclonal, 1:5000, Sigma Aldrich), alpha-tubulin (mouse-polyclonal, 1:5000, 
Abcam), MAP2 (mouse-monoclonal, 1:1000, Millipore, MAB3418), MAP6/STOP (mouse-monoclonal, 
1:1000, Millipore, MAB5524) and EB3 (rat-monoclonal, 1:200, Abcam, AB53360), with GAPDH (rabbit pol-
yclonal, 1:5000, Millipore) and alpha-tubulin (mouse-monoclonal, 1:5000, Abcam) used as loading controls. 
Secondary HRP conjugated antibodies (DAKO anti-mouse and rabbit, 1:5000; Invitrogen anti-rat, 1:2000) 
were incubated for 1.5 hours, followed by rinsing with TBS-T. Membranes were then probed by incubat-
ing with Immobilon chemiluminescence HRP substrate (Millipore) for 5 mins, followed by detection with 
Chemi-Smart 5000 image station (Vilber Lourmat). Band quantitation was completed using densitometry 
analysis in ImageJ. Blot stripping was completed using Restore Western Blot Stripping Buffer (Thermo Fisher 
Scientific, 21059).
Statistical analysis. Neuronal growth, development and function was statistically analysed using GraphPad 
Prism (Version 5.00, La Jolla, CA), with data representing percentage change from vehicle controls undergo-
ing ‘remove baseline’ functions. All data was compared to vehicle using one-way analysis of variance (ANOVA) 
with Dunnets post-hoc correction for multiple comparisons. p < 0.05 was considered significant. Data is 
expressed ± standard error of the mean (SEM) and normalised to vehicle controls. Unless otherwise stated, a 
minimum of three separate cultures was used for each experiment, with three technical replicates per culture 
(n = 3).
Results
Epothilone D induces cellular toxicity and limits neuronal maturation in a dose and time 
dependant manner. Pharmacological stabilisation of microtubules is associated with neurotoxicity and 
microtubule dependent neuronal dysfunction20,21. We hypothesised that EpoD would have dose dependant effects 
on neuronal viability, development and survival in vitro. To assess the effect of microtubule stabilisation on neu-
ronal viability and the capacity for neurite extension, we performed an AlamarBlue® cell viability assay, nuclear 
morphology analysis and evaluation of neurite extension of immature embryonic YFP positive mouse cortical 
neurons. EpoD was administered to developing cultures by bath application in concentrations of 0.1 nM, 1 nM, 
10 nM and 100 nM, which was replaced at 24 hour time intervals for 4 days28,38,39.
Developing neurons treated with varying doses of EpoD showed no significant (p > 0.05) changes in neuronal 
viability compared to vehicle treated control neurons at 1DIV (Fig. 1A). At 2DIV, 100 nM EpoD treated cultures 
showed significantly (p < 0.05) reduced cell viability by 32%, vehicle treated control neuron (Fig. 1B).
By 3DIV (two days of recurrent treatment), the percentage viability was significantly (p < 0.01 and p < 0.001) 
reduced by 18% in 10 nM EpoD treated cultures and 37% in 100 nM EpoD treated cultures, compared to vehicle 
treated controls (Fig. 1C). Cell viability decreased further, to 35% in 10 nM EpoD treated cultures and 56% in 
100 nM EpoD, when compared to vehicle treated controls (Fig. 1D), suggesting that higher doses of EpoD are 
detrimental to neuronal cell growth and survival.
Evaluation of nuclear morphology35 was also used as a readout for gross EpoD toxicity in neurons, to better 
estimate the lethal dose range in vitro. YFP positive neurons showed a significant (p < 0.05) 38% decrease in 
healthy nuclei in cultures treated with 100 nM of EpoD for 24 hours (1DIV), compared to a age matched vehi-
cle controls (Fig. 1E). This data suggests that we have selected two sublethal doses (0.1 nM and 1 nM) and two 
lethal doses (10 nM and 100 nM) of EpoD, as indicated in the legend of Fig. 1, and will be colour coded as such 
henceforth.
Previous reports demonstrate that correct microtubule function is necessary for neurite extension during 
neuronal development40. Neurite outgrowth was evaluated in YFP positive neurons with healthy nuclear mor-
phology and robust YFP positive cytoplasmic volume (Fig. 1F,G). A large proportion of vehicle treated neurons 
presented with neurite extensions by 1DIV (Fig. 1F,G), whereas both lethal 10 nM and 100 nM EpoD treated 
cultures showed a significant (p < 0.05 and p < 0.001) 18% and 48% decrease in the proportion of neurons with 
neurite extensions compared to vehicle treated controls, respectively. By 2, 3 and 4DIV, the proportion of neurons 
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Figure 2. Alterations to neurite growth and complexity in EpoD treated immature cortical neurons. (A) 
Example tracings of YFP neurons at 1DIV show decreased neurite complexity when treated with EpoD, 
compared to vehicle treated neurons (tau positive axonal process, closed arrowhead; tau negative dendritic 
process, open arrowhead). Scale = 45 μm. (B) Total length of axonal processes are not significantly (p > 0.05) 
altered due to EpoD treatment, (C) however, the total length of dendritic processes are significantly (p < 0.05) 
decreased at higher doses of EpoD. Data reported as mean ± SEM, ANOVA with Dunnett post-hoc test. (D) 
The proportion of secondary order axonal processes is significantly (p < 0.05) decreased in 10 nM and 100 nM 
EpoD treated YFP neurons and similarly, (E) the proportion primary order dendritic processes is significantly 
(p < 0.01) reduced in 10 nM and 100 nM EpoD treated YFP neurons. Data reported as mean ± SEM, ANOVA 
with Tukey’s post hoc-test. (F) Example tracings of YFP neurons at 4DIV show decreased neurite complexity 
when treated with EpoD, compared to vehicle treated neurons (tau positive axonal process, closed arrowhead; 
tau negative dendritic process, open arrowhead). Scale = 75 μm. (G) Total length of axonal processes are 
significantly (p < 0.001) decreased in 10 nM and 100 nM EpoD treated YFP neurons. (H) Total length of 
dendritic processes are significantly (p < 0.05) decreased in 0.1 nM, 10 nM and 100 nM EpoD treated YFP 
neurons. Data reported as mean ± SEM, ANOVA with Dunnett post hoc-test. (I) The proportion of secondary 
order axonal processes is significantly (p < 0.001) decreased in 10 nM and 100 nM EpoD treated YFP neurons. 
Tertiary order processes are also significantly decreased (p < 0.01) in 1 nM and 10 nM EpoD treated YFP 
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with neurites was comparable to vehicle controls (Fig. 1F), suggesting that high lethal doses of EpoD inhibit initial 
neurite outgrowth in primary cortical neurons; however, surviving neurons are able to sprout processes at later 
stages of development, irrespective of EpoD concentration.
The impact of epothilone D on neurite complexity in primary cortical neurons. As well as being 
important for neurite initiation and the induction of neuronal polarity, microtubules are also important for 
axonal and dendrite growth and the development of circuit complexity41,42. To determine whether EpoD treat-
ment has microtubule dependant effects on these parameters, developing YFP positive cortical neurons were 
treated with varying doses of EpoD, followed by evaluation of tau positive (axon henceforth) and tau nega-
tive (dendrites henceforth) neurite process complexity at 1DIV and 4DIV. Treatment with 10 nM and 100 nM 
EpoD was found to decrease the complexity of YFP cortical neurons at 1DIV, compared to vehicle treated neu-
rons (Fig. 2A). Although there was a subtle increase in axonal lengths in 01.nM and 1 nM EpoD treated cul-
tures, this was not significant (p > 0.05) when compared to vehicle treated controls at 1DIV (Fig. 2B). However, 
dendritic processes at 1DIV were significantly (p < 0.05) shorter in both 10 nM and 100 nM EpoD treated 
YFP cortical neurons, compared to vehicle treated controls (10 nM EpoD: 20.95 μm ± 4.75 μm; 100 nM EpoD: 
23.08 μm ± 9.14 μm; vehicle: 41.81 μm ± 15.97 μm) (Fig. 2C). The complexity of secondary order axonal pro-
cesses was significantly reduced in 10 nM and 100 nM EpoD treated neurons, compared to vehicle controls at 
1DIV, with no 100 nM treated neurons containing tertiary order process at 1DIV (10 nM EpoD: 9.14% ± 15.14%; 
100 nM EpoD: 7.57% ± 11.88%; vehicle: 28.41% ± 4.87%) (Fig. 2D). Similarly, the proportion of YFP neurons 
with primary order dendritic processes was also significantly decreased in 10 nM and 100 nM EpoD treated 
cultures (10 nM EpoD: 42.17% ± 21.14%; 100 nM EpoD: 29.26% ± 10.11%; vehicle: 76.47% ± 21.51%) (Fig. 2E). 
There was no significant (p > 0.05) difference in the complexity of dendritic secondary and tertiary processes due 
to EpoD treatment at 1DIV (data not shown).
Similar to treatments at 1DIV, 10 nM and 100 nM concentrations of EpoD were found to reduce the com-
plexity of cortical neurons at 4DIV, compared to vehicle treated neurons (Fig. 2F). YFP neurons treated with 
10 nM and 100 nM EpoD for four days have a significantly reduced (p < 0.05) total axonal process length, com-
pared to vehicle treated controls (10 nM EpoD: 214.24 μm ± 44.15 μm; 100 nM EpoD: 141.81 μm ± 42.69 μm; 
vehicle: 479.31 μm ± 145.60 μm) (Fig. 2G). Similarly, dendritic processes exhibit significantly (p < 0.05) reduced 
total process length when treated with 0.1 nM, 10 nM and 100 nM of EpoD, compared to vehicle treated con-
trols (10 nM EpoD: 93.81 μm ± 16.18 μm; 100 nM EpoD: 80.87 μm ± 19.32 μm; vehicle: 170.49 μm ± 15.59 μm) 
(Fig. 2H). Branching complexity at 4DIV in YFP neurons revealed that primary order axonal processes were 
not significantly (p > 0.05) altered due to EpoD treatment (Fig. 2I). However, secondary order axonal processes 
were significantly (p < 0.01) decreased in 10 nM and 100 nM EpoD treated YFP neurons, compared to vehicle 
treated controls (10 nM EpoD: 38.91% ± 38.87%; 100 nM EpoD: 10.23% ± 11.16%; vehicle: 93.75% ± 7.98%) 
(Fig. 2I). Tertiary order axonal processes were also significantly (p < 0.001) decreased in 1 nM and 10 nM EpoD 
treated YFP neurons, with 100 nM EpoD treated YFP neurons exhibiting no tertiary order processes (1 nM EpoD: 
28.66% ± 20.74%; 10 nM EpoD: 11.52% ± 14.28%; vehicle: 78.89% ± 17.00%) (Fig. 2I). Evaluation of branching 
complexity of dendritic processes at 4DIV showed a significant (p < 0.001) decrease in the proportion of pri-
mary processes in 10 nM and 100 nM EpoD treated YFP neurons, compared to vehicle treated controls (100 nM 
EpoD: 60.96% ± 6.14%; vehicle: 100% ± 0%) (Fig. 2J). However, there was no significant (p > 0.05) decrease in 
the proportion of secondary processes in EpoD treated YFP neurons (data not shown). These results suggest that 
EpoD impacts on the growth and complexity of both axons and dendrites, with sub lethal 1 nM, and lethal 10 nM 
and 100 nM concentrations of EpoD impeding neurite outgrowth in YFP cortical neurons. It also suggests that 
although 10 nM and 100 nM concentrations of EpoD decrease cell viability and complexity, a subset of cortical 
neurons are able to develop complex neurite architecture.
epothilone D alters microtubule associated proteins involved in microtubule regulation and 
stability. Our laboratory26,43, and others44, have previously used acetylated tubulin levels to measure the sta-
bilising potential of Epothilone D. We have previously reported that cortical neurons treated for two hours with 
100 nM of EpoD have markedly increased levels of tubulin acetylation in vitro. Indeed, in the current study we 
treated 10DIV culture cortical neurons with EpoD and evaluated a number of microtubule stability markers and 
microtubule associated proteins (MAPs). Primary cortical neurons at 10DIV were considered relatively mature, 
as an increase in synaptic proteins, glutamate receptors, axon/dendrite connections and altered electrophysio-
logical properties occur at this age, and is associated with improved neuronal viability, a necessary phenomenon 
needed to evaluate any toxicity attributed to by EpoD45,46. 100 nM EpoD treated cultures showed significantly 
(p < 0.05) higher levels of acetylation after 24 hours, compared to vehicle treated controls (Fig. 3A). Analysis of 
specific MAP levels showed that EpoD alters the expression of MAP2, a protein involved in the stabilisation of 
microtubules, specifically in dendrites, significantly increasing (p < 0.01) in 0.1 nM EpoD treated cultures, and a 
significant decrease in MAP2 protein levels in 100 nM EpoD treated cultures, compared to vehicle treated con-
trols (Fig. 3B). End binding protein 3 (EB3) is a microtubule + TIP protein that is associated with the growing 
neurons, with no tertiary order axonal process in 100 nM treated cells. (J) The proportion of primary order 
dendritic processes is significantly (p < 0.05) reduced in 10 nM and 100 nM EpoD treated YFP neurons. 
Circles in example traces represent branch points. Data reported as mean ± SD, ANOVA with Tukey’s post 
hoc-test. All data n = 4 cultures, performed in triplicate. Abbreviations: DIV, days in vitro; EpoD, epothilone 
D; nM, nanomolar; SEM, standard error of the mean; YFP, yellow fluorescent protein. *p < 0.05, **p < 0.01, 
***p < 0.001, ****p < 0.0001.
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‘plus’ end of microtubules47. Others have reported that microtubule stabilising compounds drastically reduce EB3 
expression and localisation20,21,48. Evaluation of EB3 protein levels by Western blot reveal 24 hours after treatment 
EB3 was significantly (p < 0.01) decreased in neurons treated with 100 nM of EpoD, with no changes in neurons 
treated with lower concentrations (Fig. 3C). MAP6, previously known as Stable Tubulin Only Peptide (STOP), 
is a MAP that is associated with the stable domains of the microtubule network49. Treatment of cultures with 
EpoD revealed that MAP6 levels are significantly (p < 0.05) increased in neurons treated with 10 nM of EpoD, 
compared to vehicle treated control neurons (Fig. 3D). Surprisingly, MAP6 levels in 100 nM EpoD treatments 
Figure 3. Representative cropped examples of western blot data. (A) Tubulin acetylation, a marker of 
microtubule stability, is increased in 100 nM EpoD treated cortical neuronal cultures. (B) Western blots of 
MAP2 protein levels, (C) EB3 protein levels, and (D) MAP6 protein levels, compared to GAPDH loading 
controls. Data reported as mean ± SD, n = 3 cultures, performed in duplicate, ANOVA with Dunnett post hoc 
test. Abbreviations: DIV, days in vitro; EB3, end binding protein; MAP2, microtubule associated protein 2; nM, 
nanomolar; NFM, neurofilament medium chain; SD, standard deviation; STOP; MAP6, microtubule associated 
protein 6. Full blot examples are presented in the Supplementary Figure.
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were comparable to vehicle treated controls, most likely due to the loss of neuronal viability (and thus neuronal 
numbers in the culture). Collectively, MAP analysis suggests that alterations to microtubule protein levels are 
dose dependent following EpoD treatment.
epothilone D alters cellular viability of relatively mature cortical neurons. Microtubule targeting 
compounds, such as EpoD, are generally only used in humans with established cortical structures and circuitry, 
and typically only in the second and third trimester of pregnant mothers50. Therefore, to determine the effect on 
neurons with established networks, we investigated the impact of EpoD treatment at 10DIV, a stage where cortical 
neuronal cultures are relatively mature in vitro, and neurons begin to develop functional synaptic connections, 
and have robust viability26. Relatively mature primary cortical neurons at 10DIV were treated with varying doses 
of EpoD and neuronal viability was assessed at 24 hours post-treatment. At 24 hours post-treatment, 10 nM and 
100 nM concentrations of EpoD were found to significantly (p < 0.05 & 0.001) reduce cell viability by 16% and 
36% respectively, compared to vehicle treated controls (Fig. 4A). Similar results were observed upon evalua-
tion of nuclei morphology in YFP expressing neurons at 24 hours post treatment, showing that 10DIV neurons 
treated with EpoD had a significant (p < 0.01) 19% decrease in healthy nuclei in 10 nM treated cultures, and a 
16% decrease in 100 nM treated cultures, compared to vehicle treated controls (Fig. 4B). These results suggest 
that treatment of relatively mature (10DIV) primary cortical neurons with EpoD has dose dependant effects on 
neuronal viability. Neurofilament medium chain (NFM) immunolabeling was used as a marker of cytoskeletal 
and cellular integrity. Fluorescence microscopy and subsequent image analysis using thresholding and particle 
analysis revealed that the area of neurofilament medium chain (NFM) immunolabelling, a neuronal specific 
cytoskeletal intermediate filament protein, significantly (p < 0.05) decreased in 100 nM EpoD treated cultures 
(Fig. 4C,E). Similarly, YFP immunofluorescence was significantly decreased (p < 0.05) at 100 nM EpoD treatment 
conditions with no change at lower concentrations (Fig. 4D & F). To determine if the change in NFM reflected a 
change in neurofilaments or overall cell loss, the amount of NFM in YFP neurons was determined through colo-
calization analysis. There was no significant differences (p > 0.05) in any of the treatments, indicating that NFM 
expression per se is not effected in the YFP excitatory neurons (Fig. 4G).
epothilone D impairs mitochondrial transport in cortical neurons in vitro. Altered microtubule 
stability has been shown to directly impact microtubule dependant transport in both neurodegenerative diseases, 
such as Amyotrophic Lateral Sclerosis51,52, and during treatment with the microtubule stabilising compound 
Taxol21. Therefore, we hypothesised that treatment of cortical neurons with EpoD would impact mitochondrial 
transport in vitro. Bi-directional microtubule dependant transport was analysed in relatively mature 10DIV cor-
tical neurons by fluorescently labelling mitochondria, followed by live cell imaging. In vehicle treated control cul-
tures, mitochondrial transport is readily observed (Fig. 5A), but is decreased in EpoD treated cultures (Fig. 5B). It 
was determined that after two hours treatment the maximum transport speed of mitochondria decreases signifi-
cantly (p < 0.01) by 25% in 100 nM EpoD treated cultures, compared to vehicle treated controls (Fig. 5C). Further, 
the average transport speed of mitochondria two hours after treatment decreased significantly (p < 0.001) by 28% 
in 10 nM EpoD treated neurons and 38% in 100 nM EpoD treated neurons, compared to vehicle treated controls 
(Fig. 5D). We also evaluated the proportion of moving mitochondria two hours after treatment, with 10 nM EpoD 
causing a significant (p < 0.01) 13% and 100 nM EpoD 18% decrease in the proportion of moving mitochondria 
in cultured cortical neurons, compared to vehicle treated controls (Fig. 5E).
24 hours post treatment the maximum transport speed of mitochondria was significantly (p < 0.05) reduced 
by 28% in 0.1 nM EpoD treated neurons, and 38% in 100 nM EpoD treated cortical neurons, compared to vehi-
cle treated controls (Fig. 5F). Further, the average transport speed of mitochondria 24 hours after treatment is 
significantly (p < 0.05) decreased by 21% in 1 nM, 36% in 10 nM, and 46% in 100 nM EpoD treated neurons, 
compared to vehicle treated controls (Fig. 5G). The proportion of moving mitochondria was significantly 
(p < 0.0001) reduced by 14% in 10 nM and 23% in 100 nM EpoD treated neuronal cultures, compared to vehicle 
treated controls (Fig. 5H). Comparisons of measurement outcomes between the two and 24 hour treatment time 
points reveal that there was no significant (p > 0.05) difference in the maximum speed of mitochondria (Fig. 5I). 
However, there was a significant (p < 0.05) decrease in the average transport speed of mitochondria in 0.1 nM 
EpoD treated cultures (Fig. 5J). Further, there was a progressive loss (p < 0.01) in the proportion of moving mito-
chondria between the two hour and 24 hour cultures in the 0.1 nM and 100 nM EpoD treated cultures (Fig. 5K). 
These results suggest that EpoD impairs mitochondrial transport in a dose and time dependent manner, with 
increasing concentrations having a progressively detrimental effect on transport speed over time. Furthermore, 
this data indicates that even a sub lethal dose of EpoD, which has no detectable effects on cell health or microtu-
bule dependent neurite outgrowth, can have a significant effect on microtubule dynamics.
Discussion
Targeting microtubules as a pharmacological intervention is becoming an increasingly attractive and investigated 
therapeutic strategy for various neurodegenerative diseases and injury26–29,44. However, despite the increased use 
of these CNS penetrant MSAs, the consequence of cortical neuron exposure is still poorly understood53. The cur-
rent study investigated the impact EpoD has on growth, survival and function of cortical neurons in vitro, with 
the aim of evaluating EpoD toxicity in cortical neurons. EpoD was hypothesised to alter microtubule dependant 
outcomes, such as neurite growth, complexity and length, microtubule stability, microtubule dependant transport 
and cellular viability in a dose dependant manner. Our study highlights that EpoD impairs various aspects of 
cortical neuron growth, development and maintenance.
The concentration range of EpoD used in the current study aimed to reflect EpoD concentrations CNS neu-
rons experience as reported in in vivo therapeutic trials. It has been suggested that in in vivo trials administra-
tion of EpoD (1–3 mg/kg) leads to EpoD retainment in the CNS at bioactive levels in vivo for days, with cells 
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Figure 4. Cellular viability of EpoD treated relatively mature cortical neurons. (A) 24 hours post treatment; 
10 nM (p < 0.05) and 100 nM (p < 0.001) concentrations of EpoD are detrimental to cell viability, (B) and 
nuclear morphology (p < 0.01), in cortical neurons. (C) Neurofilament medium chain (NFM) immunostaining 
was used as a marker of cytoskeletal and cellular integrity. Treating cortical neurons with 100 nM of EpoD 
altered the appearance and fluorescence levels of NFM immunostaining, compared to vehicle control treated 
cultures, and lower EpoD concentrations. (D) Endogenously expressed YFP fluorescence appeared reduced in 
the higher 100 nM EpoD concentration treated cells. Scale = 120 μm. (E) The area of NFM immunofluorescence 
is significantly (p < 0.05) reduced in 100 nM EpoD treated cultures. (F) The area of YFP immunofluorescence 
is significantly (p < 0.05) decreased in 100 nM EpoD treated cultures. (G) The ration of NFM colocalizing 
with YFP was not significantly changed at any EpoD concentrations. Data reported as mean ± SEM, n = 3 
cultures, performed in duplicate, ANOVA with Dunnett post hoc test. Abbreviations: DIV, days in vitro; EpoD, 
epothilone D; nM, nanomolar; NFM, neurofilament medium chain; SEM, standard error of the mean; YFP, 
yellow fluorescent protein. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 5. Mitochondrial transport in EpoD treated cortical neurons at 10DIV. (A) Mitochondrial transport 
(arrows) in a vehicle treated axonal bundle, (B) and an EpoD treated axonal bundle. (C) The maximum speed of 
mitochondria two hours post EpoD treatment is significantly decreased in 100 nM (p < 0.01) treated neuronal 
cultures. (D) Similarly, the average speed of mitochondria two hours post treatment is significantly decreased 
in 10 nM (p < 0.01) and 100 nM (p < 0.0001) EpoD treated neuronal cultures. (E) The proportion of moving 
mitochondria is significantly decreased in 10 nM (p < 0.001) and 100 nM (p < 0.0001) EpoD treated neuronal 
cultures. (F) The maximum speed of mitochondria 24 hours post EpoD treatment is significantly decreased 
in 10 nM (p < 0.05) and 100 nM (p < 0.001) EpoD treated neuronal cultures. (G) Similarly, the average speed 
of mitochondria 24 hours post treatment is significantly decreased in 1 nM (p < 0.05), 10 nM (p < 0.0001) 
and 100 nM (p < 0.0001) EpoD treated neuronal cultures. (H) The proportion of moving mitochondria is 
significantly (p < 0.0001) decreased in 10 nM and 100 nM EpoD treated neuronal cultures 24-hour post 
treatment. (I) The maximum speed of moving mitochondria does not change between two and 24 hour 
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experiencing low nanomolar concentrations of EpoD28,38,39,44. Our results suggest that CNS neurons treated with 
even relative low doses in vivo may be experiencing microtubule dependent dysfunction, particularly when con-
sidering organelle transport and general neuronal metabolic activity. Interestingly, treating various types of neu-
rons with EpoB exhibits both beneficial and negative effects depending on neuronal subtype, dosage and the age 
of the neurons32. For example, EpoB was found to decrease cell viability and prevent axonal growth at nanomolar 
concentrations. However, the authors report that picomolar concentrations of EpoB promoted axonal growth in 
cortical neurons, a phenomenon not identified in the current study utilising EpoD. Our laboratory has previously 
shown that 0.1 nM concentrations of EpoD promote axonal regeneration in a scratch assay injury model, sup-
porting the use of sub nanomolar concentrations of EpoD to improve neuronal growth26. More recently we have 
shown a mixture of beneficial and detrimental outcomes follow therapeutic administration of EpoD in an ALS 
mouse model43. Wild type littermates in this study receiving the same dose of EpoD (2 mg/kg) showed no aber-
rant behavioural, neuronal degeneration or glial activation phenotypes. This suggests that MSAs such as EpoD 
can have a wide range of effects, which can be dependent upon the disease being targeted, cell types involved and 
the dosing and timing of such experiments. Indeed, this difficulty in relating dose, treatment timing and innate 
differences in bioavailability between in vitro and in vivo models reaffirms that evaluation of differential cellular 
responses in regard to MSA’s is required to understand the impact of these compounds.
Our study identified that EpoD concentrations similar to those reported in the CNS of EpoD treated mice 
are neurotoxic to cultured cortical neurons. We investigated cortical neurons at two time points, when they were 
developing and when then become relative mature in vitro at 10 DIV, a time point where the neurons have com-
plex network connections and are synaptically mature. Indeed, EpoD was found to decrease cell viability and 
growth, and impair microtubule transport, particularly in neuronal cultures treated with high, lethal concentra-
tions of EpoD. Intriguingly, although high concentrations of EpoD are detrimental to neuronal health and the 
initiation of neurite process extension, our data suggests that large proportions of neurons survive and extend 
processes, albeit with impacted growth rates and complexity, irrespective of EpoD concentrations. Similar to our 
study, treatment of cultured sensory neurons with high concentrations of Taxol results in a population of neurons 
that survive, but with inhibited neurite formation, whereas lower doses of Taxol do not alter survival or neurite 
outgrowth54. Golovyashkina and Colleagues (2015), reported that 0.2 nM of EpoD causes dendritic simplification, 
whereas higher concentrations cause decreased neuronal survival in cultured CA1 hippocampal neurons39. Our 
data suggests that both sublethal and lethal concentrations of EpoD concentrations cause significant alterations 
to neurite growth and complexity. Indeed, both axonal and dendritic shortening and simplification occurs to 
neurons treated with EpoD. Recently we published data showing EpoD administration in vivo causes increased 
dendritic spine density in layer 5 pyramidal projection neurons, without pyramidal cell loss, highlighting the 
capacity for EpoD to alter different cell types and targets55. This difference in EpoD concentration required to 
cause alterations may suggest a differential vulnerability to EpoD between neuronal populations, similar to that 
of EpoB, as mentioned previously32,39. Further, differences in the vulnerability of neuronal compartments to EpoD 
were identified in the current study, with only dendrite length being affected at sublethal concentrations, whilst 
lethal concentrations impacted both axon and dendrite readouts. It would be important in future studies to deter-
mine the mechanisms of the differences that may exists between different Epothilones, such and EpoD and EpoB, 
as our research, in agreement with others is indicating that whilst these two different drugs exhibit similarities, 
they may have also have very different effects depending upon the cell type and parameter investigated.
We report that EpoD causes dose dependent alterations to the cellular localisation and protein levels of various 
MAPs. As EpoD concentrations increase, so do markers of stability (acetylation and MAP6), whilst EB3 protein 
levels decrease only at high, lethal concentrations, suggesting that the microtubule network becomes increasingly 
stabilised. Both tubulin acetylation and EB3 comets have been previously used as biomarkers for microtubule 
stability21,47,48,56. Pharmacological hyperstabilization of microtubules decreases the density of EB3 + TIPs, thus 
signifying a reduction in microtubule dynamics and increased microtubule stability21. Indeed, a similar phe-
nomenon occurs in vivo, where microtubule stabilization in mice suppressed EB3 immunofluorescence in the 
sciatic nerve20 and decreased EB3 comets in the distal axon during phasic pruning56. This suggests that micro-
tubule stabilisation with MSAs, such as high, lethal concentrations of EpoD, causes alterations to EB3 protein 
levels and microtubule + TIP localisation. Interestingly, we identified that MAP6 protein levels are increased 
at 10 nM concentrations of EpoD, but were reduced back to levels comparable with vehicle controls in 100 nM 
EpoD treated cultures. The cause of this differential response of MAP6 protein levels is unknown. However, it 
is quite surprising, as 100 nM EpoD concentrations were shown to increase tubulin acetylation and stability, 
it would not be unreasonable to assume MAP6 levels would also be increased at this concentration of EpoD. 
MAP6, a protein that binds to microtubules in response to cold induced depolymerisation57, can be regulated 
by calmodulin58,59, and is susceptible to increasing intracellular calcium levels60. The decrease in MAP6 levels in 
100 nM EpoD treated cultures in the current study may be explained by an increase in intracellular calcium due 
to decreased cellular viability60. Interestingly, MAP6-null mice are used as a model of schizophrenia, as microtu-
bules have been implicated in the disorder30,31,61. EpoD treatment of MAP6-null mice improves this disorder by 
stabilising microtubules31, suggesting the stability properties of both MAP6 and EpoD affect stable microtubule 
domains. Investigations into whether EpoD administration causes aberrant MAP phenotypes, such as Benbow 
treatments. (J) The average speed of mitochondria in 0.1 nM EpoD treated cultures decreased between two hour 
and 24 hours treated cultures. (K) The proportion of moving mitochondria decreased in 0.1 nM and 100 nM 
EpoD treated cultures between two hours and 24 hours. Data reported as mean ± SEM, n = 10–12 cultures per 
treatment, performed in triplicate, ANOVA with Dunnett post hoc test. Scale = 50 μm. Abbreviations: DIV, days 
in vitro; nM, nanomolar; SEM, standard error of the mean. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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and Colleagues (2016) described when treating mice with taxol and describing changes to EB3 expression in vivo, 
is required to compare our current study with EpoD concentrations used for cancer therapy62. Whilst we identi-
fied the majority of changes to MAP levels occur only at lethal concentrations of EpoD, and in keeping with this 
MAP2 levels were significantly reduced at the lethal 100 nM concentration, we also identified that MAP2 levels 
were in fact increased at the sublethal concentration with 0.1 nM. This suggests that MAP2, a dendrite specific 
MAP, may have an differential response to a range of EpoD concentrations, supported by the identified changes 
to dendrite length at sublethal concentrations of EpoD, that may be titrated.
Altered microtubule stability and dynamics can also impact microtubule dependant intracellular trans-
port21,48, a phenomenon associated with pathophysiological mechanism in neurodegenerative disorders, such 
as Motor Neuron Disease51,52. Our results suggest that whilst low, sublethal concentrations and short treatment 
durations with EpoD may not impact neuronal survival and viability, subtle changes to bidirectional mitochon-
drial transport occur, with increasing concentrations having a progressively detrimental effect on transport speed 
over time. Indeed, whilst sublethal concentrations of EpoD only impact the average transport speed of mitochon-
dria after 24 hours of treatment, lethal concentrations of EpoD impact all mitochondrial readouts, regardless of 
treatment duration. Correct mitochondrial transport is imperative for neuronal survival63 and mitochondrial 
transport is important for axonal and dendrite growth64,65, which may explain the alterations in both growth and 
morphology identified in our study. Indeed, we focused on pooling analysis of axons and dendrites in our mito-
chondrial transport analysis, therefore we cannot comment directly whether anterograde transport, retrograde 
transport, or both are affected by EpoD treatment. Furthermore, it was not determined if this altered transport 
was also associated with altered function. Our viability assays, which employed the Alamar Blue assay, would be 
affected by mitochondrial dysfunction but this cannot be interoperated as a change in mitochondrial function 
alone. Taken together with aberrant neuronal development during exposure to low EpoD concentrations, we 
conclude that EpoD has wide and far-reaching effects in regard to dosage and duration of treatment.
conclusion
Microtubule targeting compounds are increasingly being considered for their therapeutic potential in various neu-
rodegenerative diseases. However, how these compounds influence normal neuronal functioning is still poorly 
understood. Our findings have important implications for both the proposed therapeutic use of low dose MSAs 
in the treatment of neurodegeneration and disease, and informing the mechanisms by which higher doses may 
provoke peripheral neuropathies. It was found that EpoD impaired normal neuronal growth and viability and 
caused dysfunction to microtubule dependant transport, at concentrations comparable to those used in previous in 
vivo preclinical neurodegenerative trials. It was found that the majority of effects on mitochondrial movement are 
caused by high, lethal concentrations of EpoD. However, our data also suggested that low sublethal concentrations 
of EpoD may affect average transport speed of mitochondria over time. These findings suggest that protracted peri-
ods of seemingly mild EpoD exposure may have consequences on mitochondrial function and that consideration 
of dose of EpoD, as well as the intended target or outcome are essential when utilising EpoD as a pharmacological 
modifier of neurodegenerative diseases and trauma. Comparisons between chronic and acute exposure, the bio-
availability of MSAs to distinct anatomical and cellular compartments, the differential vulnerability of a range of 
cell populations to MSAs, and systemic versus localised exposure during treatment are required. This is of par-
ticular importance where the microtubule network may be differentially altered in injury and disease states, thus 
making both timing and dose highly relevant. It is essential to understand the underlying impact of MSA action on 
cellular function, particularly when MSAs continue to be a possible avenue of therapeutic intervention for multiple 
neurological disorders. Future studies utilising pharmacological manipulation of microtubule stability would bene-
fit from a greater understanding of the microtubule environment, and how individual MSAs affect the cytoskeleton.
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